About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Expanded Access Program With Nivolumab to Treat Melanoma

NCT02142218·80 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Bristol-Myers Squibb

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
ECOG Performance Status of 0-1
Histologically confirmed malignant melanoma
Progressed on or after treatment with an anti-CTLA4

You may not be if

Active brain metastases
Life Expectancy \<6 weeks
Subjects who received prior therapy targeting T-cell costimulation or checkpoint pathways except for Anti CTLA-4 therapy
Subjects with autoimmune disease

The record

StatusNo longer available

PhaseNo phase

Taking part—

StartedJun 2014

UpdatedSep 29, 2016

Conditions

Stage III (Unresectable) or Stage IV Advanced Melanoma

Where80

Local Institution
Mobile, Alabama, United States
Southern Cancer Center Pc
Mobile, Alabama, United States
Local Institution
Encinitas, California, United States

Clareo Health | Expanded Access Program With Nivolumab to Treat Melanoma